|
Affiliation |
Director |
|
Laboratory Address |
5200 Kihara-Kiyotake-cho, Miyazaki City |
|
Laboratory Phone number |
+81-985-85-2968 |
|
Laboratory Fax number |
+81-985-85-6958 |
|
Homepage |
|
|
External Link |
|
|
Related SDGs |
|
KAMOTO Toshiyuki
|
|
|
Degree 【 display / non-display 】
-
博士（医学） ( 1997.7 京都大学 )
-
学士（医学） ( 1987.3 京都大学 )
Research Interests 【 display / non-display 】
-
urology, uro-oncology, laparoscopic surgery
-
腫瘍マーカー
-
腎移植
-
精巣癌
-
泌尿器腫瘍学
-
前立腺癌
-
内視鏡/体腔鏡手術
Research Areas 【 display / non-display 】
-
Life Science / Urology / urologic oncology
Education 【 display / non-display 】
-
Kyoto University Graduate School, Division of Medicine
- 1995.8
Country：Japan
-
Kyoto University Faculty of Medicine
- 1987.3
Country：Japan
Campus Career 【 display / non-display 】
-
University of Miyazaki Faculty of Medicine School of Medicine Department of Developmental and Urological-Reproductive Medicine, Urology Professor
2009.05 - 2024.09
-
University of Miyazaki Director
2024.10 - Now
-
University of Miyazaki Faculty of Medicine
2021.10 - 2024.09
-
University of Miyazaki Faculty of Medicine College Hospital
2016.04 - 2024.09
-
University of Miyazaki Faculty of Medicine
2015.10 - 2021.09
External Career 【 display / non-display 】
-
University of Miyazaki Faculty of Medicine School of Medicine Surgery study course urology study field Professor
2009.5
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 准教授
2007.4 - 2009.4
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 助教授
2003.11 - 2007.3
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 講師
2001.10 - 2003.10
-
京都大学医学部附属病院 泌尿器科 助手
1997.1 - 2001.9
Professional Memberships 【 display / non-display 】
Papers 【 display / non-display 】
-
Terada N, Mizowaki T, Saito T, Yokomizo A, Kohei N, Tabata KI, Shiota M, Takahashi A, Shimazui T, Goto T, Hashimoto Y, Fujii M, Tomida R, Sakurai T, Hashimoto K, Kawamura S, Teraoka S, Sakamoto S, Kimura T, Kamiyama M, Narita S, Tanaka N, Kato T, Kato M, Osawa T, Kojima T, Inoue T, Sugimoto M, Nishiyama H, Kamoto T, Japanese Urological Oncology Group.
BJUI compass 1 ( 5 ) 165 - 173 2020.11
Authorship：Last author Language：English Publishing type：Research paper (scientific journal) Publisher：BJUI Compass
Objectives: To evaluate the association between the use of local radiotherapy (RT) with the survival of patients with de novo metastatic prostate cancer and symptomatic local events (SLEs). Patients and methods: Patients were initially diagnosed with metastatic prostate cancer between 2008 and 2017 at 30 institutes in Japan. Prostate-specific antigen (PSA) progression-free survival (PSA-PFS) under initial androgen deprivation therapy and overall survival (OS) was compared between patients receiving local RT (RT group) and no RT (no-RT group) by multivariate Cox proportional hazard analyses. The occurrence rate of grade ≥2 SLEs was compared by multivariate logistic regression analyses. Propensity score matching (PSM) analyses were performed to compare PSA-PFS and OS of the groups in the high and low metastatic burden cohort. Results: Two hundred and five (7%) of 2829 patients received RT before PSA progression. Median PSA-PFS and OS were significantly longer in the RT group than in the no-RT group and the difference was significant in multivariate analyses (HR = 0.44, 95% CI = 0.33-0.57 and HR = 0.40, 95% CI = 0.27-0.60, respectively). The occurrence rate of grade ≥2 SLEs was significantly lower in the RT group (2%) than the no-RT group (9%) and the difference was significant in multivariate analyses (HR = 0.28, 95% CI = 0.10-0.76). Using PSM analyses, PSA-PFS and OS remained significantly different (HR = 0.64, 95% CI = 0.46-0.89 and HR = 0.47, 95% CI = 0.30-0.72, respectively), between the RT (n = 182) and the no-RT (n = 182) groups. The difference in OS was significant in the high metastatic burden cohort (HR = 0.55, 95% CI = 0.37-0.81). Conclusions: Addition of local RT to standard treatment for de novo metastatic prostate cancer patients tends to have the potential to extend survival, even in patients with high metastatic burden, and to reduce SLEs.
DOI： 10.1002/bco2.35
-
Impact of treatment volume on outcomes for patients with penile cancer at relatively low-volume centers in Japan. Reviewed
Murakami Y, Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura KI, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saito S, Kamba T
Japanese journal of clinical oncology 2026.4
Language：English Publishing type：Research paper (scientific journal)
DOI： 10.1093/jjco/hyag070
-
Circulating Tumor DNA Genomic Profiling in (223)Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study. Reviewed
Shiota M, Fujiwara M, Sumiyoshi T, Enokida H, Kamba T, Igawa T, Masumori N, Uemura H, Kamoto T, Higashijima K, Mitsunari K, Uemura H, Kobayashi T, Akamatsu S, Tokunaga S, Isoda T, Ishigami K, Eto M
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026.4
Language：English Publishing type：Research paper (scientific journal)
-
賀本 敏行
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 64 ( 4 ) 2026.4
Language：English Publishing type：Research paper (scientific journal) Publisher：Society of Nuclear Medicine
Circulating tumor DNA (ctDNA) testing has emerged as a cancer precision medicine approach. We investigated the genomic landscape and clinical utility of ctDNA in patients receiving 223Ra dichloride for bone metastatic castration-resistant prostate cancer (mCRPC). Methods: This prospective, observational, multicenter study enrolled patients treated with 223Ra for bone mCRPC. Targeted sequencing of cell-free DNA from plasma at baseline and end of treatment (EOT), along with paired leukocyte DNA, was performed using an 88-gene panel. Associations between ctDNA profiles and clinical outcomes, including biomarker response, radiographic progression-free survival (rPFS), and overall survival (OS), were analyzed. Results: Of 93 patients analyzed, ctDNA was successfully profiled in 84 baseline and 74 EOT samples, with matched data available for 68 patients. A ctDNA fraction of at least 5%, as well as TP53 alteration, PTEN alteration, and cell cycle pathway alterations at baseline were significantly associated with shorter rPFS and OS. Dynamic changes in ctDNA fraction and PTEN alteration between baseline and EOT correlated with distinct rPFS and OS. Conclusion: This study suggests the clinical utility of ctDNA profiling as both a prognostic and a monitoring tool in patients with bone mCRPC treated with 223Ra. The findings obtained in this study raise the possibility that ctDNA could contribute to future strategies for risk stratification or treatment monitoring during 223Ra therapy.
-
Hatakeyama S., Yamamoto K., Yamamoto H., Yasui T., Kamoto T., Ito A., Kikuchi E., Kume H.
International Journal of Urology 33 ( 4 ) e70450 2026.4
Language：English Publishing type：Research paper (scientific journal) Publisher：International Journal of Urology
Objective: To describe real-world disease-free survival (DFS) and overall survival (OS) after radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) in Japan using nationwide data from the National Clinical Database (NCD). Methods: This nationwide descriptive study included patients with MIBC who underwent RC and were registered in the NCD in 2020. Demographic and clinical characteristics, including age, sex, surgical approach, neoadjuvant chemotherapy (NAC), and pathological stage, were summarized. DFS and OS were estimated using the Kaplan–Meier method. Survival outcomes were descriptively compared across age groups, sex, NAC status, and surgical approach without adjustment for baseline characteristics. Results: A total of 3773 patients were analyzed. The cohort showed an advanced age distribution, with 41% aged ≥ 75 years. Robotic-assisted RC was the most frequently performed approach (44%), and NAC was administered in 52% of patients. Survival declined progressively with increasing age, with the poorest outcomes observed in patients aged ≥ 80 years. Female sex and nonreceipt of NAC were associated with modestly lower DFS and OS in unadjusted analyses. Robotic-assisted and laparoscopic RC demonstrated comparable DFS and OS, whereas open RC was associated with less favorable survival outcomes. Conclusions: This nationwide descriptive analysis provides a comprehensive snapshot of real-world survival after RC for MIBC in Japan. This nationwide data reveal marked heterogeneity in patient characteristics, treatment patterns, and outcomes, and provide a foundation for identifying clinically relevant hypotheses for future risk-adjusted analyses.
DOI： 10.1111/iju.70450
Books 【 display / non-display 】
-
賀本 敏行, 都築 豊徳（ Role： Sole author）
総合医学社 2021 （ ISBN:9784883787203 ）
-
高橋 悟, 賀本 敏行, 菊地 栄次, 杉本 幹史, 安井 孝周, 赤座 英之（ Role： Sole author）
医学図書出版 2021 （ ISBN:9784865174519 ）
Language：Japanese Book type：Scholarly book
-
今日の診療のためにガイドライン外来診療2015
泉孝英、他（ Role： Joint author）
日経メディカル開発 2015.3
Language：Japanese Book type：Scholarly book
-
国試カンファレンス あなむね
賀本敏行、神波大己、他（ Role： Joint author）
医学評論社 2014.6
Language：Japanese Book type：Scholarly book
-
第109回医師国家試験問題解説書
賀本敏行、他（ Role： Joint author）
医学評論社 2014.4
Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
Future direction of urologic surgery - What should we learn from the change of surgical procedure
Kamoto T., Sugimoto M.
Nishinihon Journal of Urology 82 ( 1 ) 3 - 4 2020.4
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Nishinihon Journal of Urology
-
【なぜそれが大切?術式別観察ポイントとその根拠】 尿管皮膚瘻造設術の観察ポイントとその根拠
向井尚一郎, 深尾理, 賀本敏行
泌尿器ケア 17 ( 10 ) 985 - 989 2012.10
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：メディカ出版
-
【泌尿器病理I-前立腺と腎臓-】 今日の前立腺癌の治療法
月野浩昌, 賀本敏行
病理と臨床 30 ( 9 ) 941 - 948 2012.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：文光堂
-
【明日を見据えた前立腺癌診療】 Key words 前立腺癌の今後の薬物療法への期待
賀本敏行
カレントテラピー 30 ( 9 ) 968 - 969 2012.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：ライフメディコム
-
【骨転移のマネジメント】 前立腺癌治療と骨転移マネジメント
賀本敏行
癌と化学療法 39 1178 - 1182 2012.7
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：癌と化学療法社
Presentations 【 display / non-display 】
-
進行性/去勢抵抗性前立腺癌治療に於ける骨マネジメントー骨転移治療のポイントは？－
賀本敏行
第69回西日本泌尿器科学会総会
Event date： 2017.11.9 - 2017.11.12
Language：Japanese Presentation type：Public lecture, seminar, tutorial, course, or other speech
-
Differential use of chemotherapy and novel hormone therapy for castration-resistant prostate cancer
賀本敏行
第15回日本臨床腫瘍学会学術集会
Event date： 2017.7.27 - 2017.7.29
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
Update on Prostate Cancer Biopsy Reporting International conference
賀本敏行
Advancements in Urology 2017 in San Diego
Event date： 2017.1.11 - 2017.1.14
Language：Japanese Presentation type：Public lecture, seminar, tutorial, course, or other speech
-
泌尿器細胞診報告様式 2015 に沿った細胞診断ーリスクの検証ー
賀本敏行
第55回日本臨床細胞学会秋季大会
Event date： 2016.11.19
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
去勢抵抗性前立腺癌とは
賀本敏行
日本病理学会第 10 回診断病理サマーフェスト
Event date： 2016.9.4
Language：Japanese Presentation type：Oral presentation (invited, special)
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
転移性CRPCにおける、HGF/METパスウェイを標的とした新規治療法の開発
Grant number：23K08737 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 挑戦的研究(萌芽)
Authorship：Principal investigator
-
ヒト化マウスを用いた腎細胞癌PDXモデルの樹立とMET阻害薬効果予測因子の同定
Grant number：22K09506 2022.04 - 2025.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
Authorship：Coinvestigator(s)
-
CRPCにおけるCAVEOLIN-1,2関連シグナルを介した新規治療法の探索
Grant number：15K10597 2015.04 - 2018.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
去勢抵抗性前立腺癌に対するCAVEOLINを介する新規治療法を開発する。
-
進行性前立腺癌における新しい治療ターゲットの探索
Grant number：24592398 2012.04 - 2015.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
進行性前立腺癌における新しい治療ターゲットの探索
Past consigned research fund received 【 display / non-display 】
-
A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
2018.08 - 2022.04
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer
2017.04 - 2022.11
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormonesensitive Prostate Cancer (mHSPC)
2016.02 - 2022.03
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 inCombination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
2015.10 - 2021.12
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
2015.04 - 2021.03
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
Available Technology 【 display / non-display 】
-
泌尿器科領域悪性腫瘍における浸潤・転移機構の解明
腎無形成マウスモデルを使用した尿管芽浸潤障害 (FUBI)の解明
宮崎泌尿器科がんデータベース(MUCD)を用いたがん診断と治療の検証Related fields where technical consultation is available：泌尿器がんおよび泌尿器疾患の臨床データ、臨床サンプルの収集
泌尿器がんのゼノグラフトモデル（PDX）の作製
骨転移マウスモデルの作製Message：泌尿器腫瘍は基本的に高齢者の悪性腫瘍であり、高齢化に従って患者数、死亡者数は右肩上がりです。実際の患者さんのデータベースと、基礎研究の融合を目指しています。
Committee Memberships 【 display / non-display 】
-
日本泌尿器科学会 理事
2019.4
Committee type：学協会
NCD運営委員会委員長